How Insurers Choose Which Generics to Cover: The Truth About Formularies

Walk into any pharmacy these days, and you’ve probably seen a notice at the checkout counter. It says something about how you need to pay extra for a brand-name pill because a generic option exists. But have you ever wondered exactly how those lists get built? Why does one generic make the cut while another gets dropped? It’s not random, but neither is it always transparent.

At the heart of this system lies the concept of the insurance formulary, which is a list of approved prescription drugs covered by an insurance plan. When an insurer builds this list, they aren’t just checking boxes. They are running a complex evaluation that balances medical necessity, safety, and cost. For patients, understanding this process is the difference between paying $15 for a month’s supply of medication versus hundreds of dollars out of pocket.

The Gatekeepers: Pharmacy & Therapeutics Committees

Most people assume insurance reps sitting in an office make these calls. That isn’t true. The heavy lifting is done by Pharmacy & Therapeutics (P&T) committees, which are multidisciplinary groups of doctors, pharmacists, and specialists responsible for evaluating drug efficacy and safety. These committees operate like rigorous scientific boards rather than sales teams. They review evidence from clinical trials and real-world usage data to decide if a drug earns a spot on the list.

These panels didn’t start appearing until regulations pushed for standardization. The Medicare Modernization Act of 2003 significantly shaped their current role. Before that, rules were looser, often leaving patients guessing about coverage. Now, following mandates set in place by acts like the Affordable Care Act (ACA) in 2010, almost every commercial plan requires a structured review process. For example, data from 2023 shows that 100% of Medicare Part D plans utilize these tiered systems to organize coverage.

When a P&T committee meets, they look at three primary buckets of information:

• Clinical Effectiveness: Does the drug actually work better than existing options? If two pills do the same thing, the one with the lower price tag usually wins.
• Safety: Does the drug have fewer side effects? A newer generic with a cleaner safety profile gets a nod over an older version with known risks.
• Cost-Effectiveness: This is where the money talk happens. If Drug A saves the plan $200 a year per patient compared to Drug B, they favor Drug A, assuming both are effective.

This isn’t just theory. According to analyses by KFF, Medicare Part D plans saved over $1.67 trillion between 2007 and 2019 purely by incentivizing the use of generics over brand names. That financial pressure trickles down to the decision-making desk.

Understanding the Tier System

Once a drug is approved for coverage, it needs a home. Insurers organize formularies into levels called "tiers." Think of it like a restaurant menu where appetizers are cheaper and entrees cost more. Your copay depends entirely on which tier your medication lands in.

In the vast majority of plans, you’ll find generics tucked firmly into Tier 1. This is the lowest cost-sharing tier. By law, Medicare Part D guidelines require that Tier 1 includes generic drugs only. If you see a generic drug placed on a higher tier, something is usually wrong, or it’s a very specific non-preferred generic. Most insurers have moved toward placing low-cost preferred generics here to encourage substitution at the point of sale.

Why do insurers put generics in Tier 1? It’s simple economics. Generic drugs cost roughly 80-85% less than their brand-name counterparts. By forcing patients to use Tier 1 options, the insurer drastically lowers their overall payout. Humana and UnitedHealthcare both confirm this structure in their 2023 plan documents, noting that Tier 1 is reserved for "low-cost generic and brand-name drugs" in some variations, but almost universally prioritizing generics.

Criteria for Inclusion: Safety and Approval

Not every generic is instantly added to the list. To be eligible for coverage, a drug must pass a strict vetting process before the P&T committee even discusses it. The foundation of this requirement is approval by the Food and Drug Administration (FDA), which is the federal agency responsible for regulating drug safety and efficacy in the US.

Blue Shield of California, for instance, explicitly states that to be included, generics must contain the same active ingredient as the brand name drug. Furthermore, they must be considered "therapeutically equivalent" by the FDA. This means the body absorbs the medicine in the same way and produces the same effect.

Sometimes, manufacturers try to game the system by changing inactive ingredients (fillers). If a patient has an allergy to lactose, and a generic switch suddenly introduces lactose as a binder, the patient suffers. Committees are becoming smarter about spotting these issues. Dr. Richard Baron from the American Board of Internal Medicine noted that modern committees evaluate "real-world evidence" to see how drugs perform in diverse populations, not just clinical trial settings.

The threshold for entry is high because once a drug is removed from a formulary, getting it back is hard work. This creates stability for insurers but frustration for patients who lose access to a specific manufacturer’s version of a generic mid-year. Regulations now require plans to notify enrollees before dropping a drug, but that window is often short.

Navigating Exceptions and Appeals

You might have a situation where your doctor insists on a brand-name drug or a specific generic that isn’t on Tier 1. This triggers what is known as an "exception request." You aren’t alone in this. Reports indicate that about 43% of patients face initial denials for non-formulary drugs.

To succeed, you need documentation showing medical necessity. Washington State guidelines illustrate what proof you need:

• Evidence that the covered drug causes adverse reactions (like severe nausea or allergic responses).
• Proof that the drug wasn’t effective when you tried it previously.
• A statement from your prescribing physician.

If you submit this, insurers must respond within three business days. If it’s an urgent case-meaning waiting puts your health at risk-they must answer within one day. Failure to respond results in an automatic approval in many regulatory environments. However, the success rate varies. The Patient Advocate Foundation found that while nearly half of patients get denied initially, 78% ultimately gain coverage through persistent exception requests.

Physicians hate this part of the job. Surveys show they spend over 13 hours a week dealing with prior authorizations. While you want to advocate for yourself, having a proactive relationship with your doctor’s office helps. They can pre-submit codes that flag your specific medical condition as requiring the non-generic option.

Freshness and Future Changes

We are standing on the edge of a shift. With the Inflation Reduction Act introducing a $2,000 annual out-of-pocket maximum for Medicare Part D starting in 2025, the landscape is changing rapidly. Insurers are recalculating their strategies to handle these caps. Analysts predict this will shift their focus even more aggressively toward high-volume generics to manage total spend.

Furthermore, the FDA’s 2023 draft guidance on "Complex Generic Drugs" aims to streamline approval for difficult-to-copy products like inhalers and insulins. This could expand the pool of available generics in areas that were previously dominated by brand names. However, shortages remain a concern. As of late 2023, there were 372 active drug shortages reported, and generics made up the majority of affected products. This instability challenges the reliability of long-term formulary listings.

Looking ahead to 2027, industry analysts project that 95% of prescriptions will have generic alternatives. This surge is driven by biosimilar competition in specialty markets. As the list of options grows, the selection criteria used by insurers will likely tighten to ensure quality doesn’t drop while costs rise.